Documente Academic
Documente Profesional
Documente Cultură
Disclaimer
The views expressed in this presentation are those of the
presenter and do not necessarily represent the views of,
and should not be attributed to, Novartis Asia Pacific
Pharmaceuticals Pte Ltd.
Spontaneous
Reports
Clinical Trial
Follow-up
Data
Literature
Reports
Data In
Regulatory
Reports
Submission
+
Study
Reports
Database
Entry
Licensing
Partners
Amend
Prescribing
Information
Data Review
Signal
Detection
Output
Enquiry
Response
Licensing
Partners
Collect
Risk
Management
Plans
Review
marketing
status
Action
World-wide
Regulatory
Reports
Expedited
& Periodic
Challenge 1:
Audit
Language barrier during audit
Challenge 2:
Question
How many adverse event report does Novartis received
each year?
a. 380,000
b. 520,000
c. 450,000
d. 290,000
Challenge 3:
Priority: Serious, unexpected > Serious, expected > Nonserious, unexpected cases
List B
country of occurrence
an identifiable reporter
an identifiable patient
source type (e.g., physician, lawyer,
regulatory authority, etc.)
a suspect drug or drugs
one or more adverse event.
List C
Stopping date and time or duration
of treatment
For concomitant medications:
Daily dose and regimen
Stopping date and time or
duration of treatment
Specific tests and or/treatment
required and their results
Setting (e.g., hospital, outpatient
clinic, home, nursing home)
Any autopsy or other post-mortem
findings
Whether or not the hospital
discharge summary is available if
the patient was hospitalized.
Anything relevant to facilitate
assessment of the case such as
medical history, relevant drug
history including allergies, drug or
alcohol abuse, family history.
Timeline
(CIOMS V Recommendation)
*Not mandatory, a reminder letter may be sent for non serious cases if deemed appropriate
28 | Presentation Title | Presenter Name | Date | Subject | Business Use Only
To focus the efforts (in terms on number of followattempts) in RMP events, Serious Fatal and Life
Threatening(F/LT) Cases/Serious Cases:
As per GPV Module VI follow ups are particularly relevant for
monitored events of special interest, and cases notifying the
death of a patient
*For NVx key event cases, the number of follow ups can be more than 3 as per the NVx procedure. CPO would be informed through
the responsible PVE/PVL
** +/- 2 calendar days
33 | Presentation Title | Presenter Name | Date | Subject | Business Use Only
Challenge 4:
Case Closures
Case Closures
Challenges
Case Closures
Solution
Case Closures
solution
Case Closures
Solution
Challenge 5:
Challenge 6:
Paper reporting
Use of paper
Electronic reporting
Electronic submission of ICSRs is a cost effective, efficient
alternative to paper-based reporting.
Electronic reporting
Challenges
Challenge 7:
Miranda Wang
Head for Country Pharmacovigilance, China
Bristol-Myers Squibb